Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

<strong>Background<br></strong> Late treatment failures after artemisinin-based combination therapies (ACTs) for falciparum malaria have increased in the Greater Mekong subregion in southeast Asia. Addition of amodiaquine to artemether–lumefantrine could provide an efficacious trea...

詳細記述

書誌詳細
主要な著者: Peto, TJ, Tripura, R, Callery, JJ, Lek, D, Nghia, HDT, Nguon, C, Thuong, NTH, van der Pluijm, RW, Dung, NTP, Sokha, M, Luong, VV, Long, LT, Sovann, Y, Duanguppama, J, Waithira, N, Hoglund, RM, Chotsiri, P, Chau, NH, Ruecker, A, Amaratunga, C, Dhorda, M, Miotto, O, Maude, RJ, Rekol, H, Chotivanich, K, Tarning, J, von Seidlein, L, Imwong, M, Mukaka, M, Day, NPJ, Hien, TT, White, NJ, Dondorp, AM
フォーマット: Journal article
言語:English
出版事項: Elsevier 2022

類似資料